AZ505

"目录号: HY-15226A

Epigenetics-

AZ505 ditrifluoroacetate 是一种有效的选择性的SMYD2抑制剂,IC50为 0.12 μM。

Histone Methyltransferase

相关产品

EPZ-6438-GSK126-GSK343-3-Deazaneplanocin A hydrochloride-EPZ-5676-EPZ015666-UNC0642-UNC1999-BIX-01294-UNC0638-EPZ004777-EPZ031686-PFI-2 hydrochloride-A-366-SGC0946-

生物活性

Description

AZ505 ditrifluoroacetate is a potent and selectiveSMYD2inhibitor withIC50of 0.12 μM.

IC50& Target

IC50: 0.12 μM (SMYD2)[1]

In Vitro

AZ505 ditrifluoroacetate is highly selective and shows an activity at submicromolar concentrations in vitro. The IC50of AZ505 for SMYD2 is 0.12?μM, which is >600-fold greater than the IC50s of AZ505 for other histone methyltransferases, such as SMYD3 (IC50>83.3?μM), DOT1L (IC50>83.3?μM) and EZH2 (IC50>83.3?μM)[1]. AZ505 is a potent and selective SMYD2 inhibitor with an IC50of 0.12 μM. The human SMYD (SET and MYND domain-containing protein) family of protein lysine methyltransferases contains five members (SMYD1-5). Moreover, AZ505 fails to inhibit the enzymatic activities of a panel of protein lysine methyltransferases. AZ505 is nominated for ITC binding study with Kdof 0.5 μM. In contrast, the calculated Kdfor the p53 substrate peptide is 3.7 μM. AZ505 binding to SMYD2 is driven primarily by entropy, which often suggests that binding is mediated by hydrophobic interactions with few specific hydrogen bonds[2].

References

[1].Komatsu S, et al. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. Br J Cancer. 2015 Jan 20;112(2):357-64.

[2].Ferguson AD, et al. Structural basis of substrate methylation and inhibition of SMYD2. Structure. 2011 Sep 7;19(9):1262-73.

©著作权归作者所有,转载或内容合作请联系作者
平台声明:文章内容(如有图片或视频亦包括在内)由作者上传并发布,文章内容仅代表作者本人观点,简书系信息发布平台,仅提供信息存储服务。

推荐阅读更多精彩内容